Robotic Surgery and Women's Health: What FDA's Safety Communications Actually Say

FDA's safety communication on robotically-assisted surgery in women's health, first issued on February 28, 2019 and updated on August 20, 2021, states that the safety and effectiveness of these devices in mastectomy procedures or in the prevention or treatment of cancer has not been established. FDA's current overview page adds that FDA has not granted marketing authorization for any robotically-assisted surgical device specifically for the prevention or treatment of cancer. This article reports what those documents say, as indexed in our FDA surgical robotics and SaMD base. It is general information, not medical advice. Decisions about your own care belong in a conversation with your health care provider.

The key statements, word for word

The core claims are short and easy to paraphrase wrongly, so they are quoted here:

• “The safety and effectiveness of using robotically-assisted surgical devices in mastectomy procedures or in the prevention or treatment of cancer has not been established.” (Safety communication, purpose section.)
• “There is limited, preliminary evidence that the use of robotically-assisted surgical devices for treatment or prevention of cancers that primarily (breast) or exclusively (cervical) affect women may be associated with diminished long-term survival.”
• “To date, the FDA has not granted marketing authorization for any robotically-assisted surgical device for use in the United States for the prevention or treatment of cancer, including breast cancer.”
• The FDA “has not granted any RAS device marketing authorization for mastectomy.” (Overview page, Q&A on the update.)

Why FDA draws the line at cancer outcomes

The explanation lies in the evidence behind existing clearances. FDA says its evaluation of these devices “has generally focused on determining whether the complication rate at 30 days is clinically comparable to other surgical techniques”. The overview page confirms that clearances for procedures commonly performed in patients with cancer, such as hysterectomy, prostatectomy and colectomy, are “based on short-term (30 day) patient follow up”.

Cancer claims would need different evidence. FDA anticipates that uses in cancer prevention or treatment “would be supported by specific clinical outcomes, such as local cancer recurrence, disease-free survival, or overall survival at time periods much longer than 30 days”. Those outcomes have not been established for these devices. FDA also notes that the labeling of legally marketed robotic systems “includes statements that cancer treatment outcomes using the device have not been evaluated by the FDA”.

The cervical cancer data FDA refers to

FDA cites peer-reviewed literature, including a limited report comparing long-term survival after radical hysterectomy for cervical cancer by open abdominal surgery versus minimally invasive surgery (laparoscopic or robotically assisted). In that report, minimally invasive surgery “appeared to be associated with a lower rate of long term survival”. FDA immediately adds that “other researchers have reported no statistically significant difference in long term survival”. The communication references the New England Journal of Medicine, November 2018. FDA's position is that clinicians and patients should be aware of this information when making treatment decisions, not that the question is settled.

FDA's recommendations, by audience

For patients

• Be aware that safety and effectiveness in mastectomy and cancer prevention or treatment have not been established.
• Discuss the benefits, risks and alternatives of all available treatment options with your health care provider.
• Ask your surgeon about their training, experience and patient outcomes with robotic procedures, how many procedures like yours they have performed, and about possible complications and how often they happen.
• If you experience a complication after treatment for a cancerous condition, FDA encourages a report through MedWatch.

For health care providers

• Understand that no robotic system has been cleared or approved on the basis of cancer-related outcomes such as overall survival, recurrence and disease-free survival.
• Take training for the specific robotic procedures you perform, and discuss your experience and expected outcomes with patients.
• Remember that U.S. clinical studies of a legally marketed device for a new intended use are subject to FDA oversight under the Investigational Device Exemption rules.

Four common misreadings

1. “FDA banned robotic mastectomy.” The documents contain no ban. FDA explains that it regulates medical devices and “generally does not regulate the practice of medicine within a health care practitioner-patient relationship”. What it says is that no device is authorized for mastectomy and that safety and effectiveness have not been established.
2. “A cleared hysterectomy robot is cleared for cervical cancer.” A clearance for a procedure, based on 30-day follow-up, is not an authorization for preventing or treating cancer.
3. “FDA certifies robotic surgeons.” FDA states that it does not supervise or accredit physician training. Training is the responsibility of manufacturers, physicians and health care facilities, sometimes supported by professional societies.
4. “Every adverse event report proves a defect.” FDA cautions that reports can be incomplete, inaccurate or unverified, and that submitting a report does not necessarily indicate a faulty device.

FDA also reminds users that there are several different models of robotic systems, which may operate differently and may not have the same functions. It advises users to learn the differences and get training on each model.

What it means for manufacturers and regulatory teams

For a medtech company, these documents set clear limits on claims. A robot cleared for a procedure is not authorized for treating the disease that motivates the procedure. FDA's draft RASD premarket guidance (issued September 25, 2026; a draft, not final) carries the same logic into labeling. It recommends a statement that outcomes related to the specific treatment of the underlying disease or condition were not evaluated as part of the authorization. It also says the umbrella and covered procedure approach cannot be used to seek authorization for treating a specific disease or condition.

• Review promotional and training materials for any implied cancer-outcome or mastectomy claims.
• Studies of unapproved uses such as cancer treatment, including those run on registry infrastructure, must be done under an IDE, according to FDA's overview page.
• Expect clinical evidence with long-term oncologic endpoints if you ever seek a cancer-related indication.
• Feed field reports into your complaint and MDR process. FDA says most RAS reports it receives are malfunctions, but it has also received reports of injuries and deaths.

FDA also encourages academic institutions, professional societies and manufacturers to set up patient registries for all uses of these devices. It notes that registries could help characterize surgeons' learning curves and long-term outcomes. To check the exact wording on any of these points, ask the base, for example “Can a company market its surgical robot specifically for breast cancer treatment?”

Sources: FDA, Computer-Assisted Surgical Systems and the 2021 update of the safety communication (archived copy). FDA says it will update the communication if significant new information becomes available, so check fda.gov for the latest version.